EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

APC/C prevents a noncanonical order of cyclin/CDK activity to maintain CDK4/6 inhibitor–induced arrest

Brandon L Mouery iD, Eliyambuya M Baker iD, Liu Mei iD, Samuel C Wolff iD, Christine A Mills, Dalia Fleifel iD, Nebyou Mulugeta, Laura E Herring iD, Jeanette Gowen Cook iD

Proceedings of the National Academy of Sciences · 23.07.2024 · 121 (30)

DOI: 10.1073/pnas.2319574121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 18.07.2024. Verfasst von Brandon L Mouery und 8 weiteren Autor:innen. Beteiligte Einrichtung: Curriculum in Genetics and Molecular Biology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 6, Cyclin-Dependent Kinase 4. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, HHS | NIH | National Institute of General Medical Sciences (NIGMS), HHS | NIH | National Cancer Institute (NCI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Regulated cell cycle progression ensures homeostasis and prevents cancer. In proliferating cells, premature S phase entry is avoided by the E3 ubiquitin ligase anaphasepromoting complex/cyclosome (APC/C), although the APC/C substrates whose degradation restrains G1-S progression are not fully known. The APC/C is also active in arrested cells that exited the cell cycle, but it is not clear whether APC/C maintains all types of arrest. Here, by expressing the APC/C inhibitor, EMI1, we show that APC/C activity is essential to prevent S phase entry in cells arrested by pharmacological cyclin-dependent kinases 4 and 6 (CDK4/6) inhibition (Palbociclib). Thus, active protein degradation is required for arrest alongside repressed cell cycle gene expression. The mechanism of rapid and robust arrest bypass from inhibiting APC/C involves CDKs acting in an atypical order to inactivate retinoblastoma-mediated E2F repression. Inactivating APC/C first causes mitotic cyclin B accumulation which then promotes cyclin A expression. We propose that cyclin A is the key substrate for maintaining arrest because APC/C-resistant cyclin A, but not cyclin B, is sufficient to induce S phase entry. Cells bypassing arrest from CDK4/6 inhibition initiate DNA replication with severely reduced origin licensing. The simultaneous accumulation of S phase licensing inhibitors, such as cyclin A and geminin, with G1 licensing activators disrupts the normal order of G1-S progression. As a result, DNA synthesis and cell proliferation are profoundly impaired. Our findings predict that cancers with elevated EMI1 expression will tend to escape CDK4/6 inhibition into a premature, underlicensed S phase and suffer enhanced genome instability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4HumansAnaphase-Promoting Complex-CyclosomeCell Line, TumorS PhasePyridinesPiperazinesCell Cycle ProteinsE2F Transcription FactorsCell Cycle CheckpointsCyclinsF-Box Proteins

Stichwörter der Autor:innen

anaphase promoting complex/cyclosome (APC/C)breast cancercell cycle arrestcyclin-dependent kinase 4/6 (CDK4/6)genome instability

Substanzen

Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4Anaphase-Promoting Complex-CyclosomeCDK4 protein, humanPyridinesCDK6 protein, humanPiperazinespalbociclibFBXO5 protein, humanCell Cycle Proteins

Autor:innen und Institutionen

  • Curriculum in Genetics and Molecular Biology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599.
  • Department of Biochemistry and Biophysics, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599.
  • Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599.
  • Immuno-Oncology, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021.
  • Computational Medicine Program, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599.
  • University of North Carolina Proteomics Core Facility, Department of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599.

ORCID-Profile: Brandon L Mouery, Eliyambuya M Baker, Liu Mei, Samuel C Wolff, Dalia Fleifel, Laura E Herring, Jeanette Gowen Cook

Förderung

  • NIGMS NIH HHS
  • HHS | NIH | National Institute of General Medical Sciences (NIGMS)
  • HHS | NIH | National Cancer Institute (NCI)
  • NCI NIH HHS
  • American Heart Association (AHA)

Zitieren

APA

Mouery, B. L., Baker, E. M., Mei, L., Wolff, S. C., Mills, C. A., Fleifel, D., Mulugeta, N., Herring, L. E., & Cook, J. G. (2024). APC/C prevents a noncanonical order of cyclin/CDK activity to maintain CDK4/6 inhibitor–induced arrest. Proceedings of the National Academy of Sciences, 121(30). https://doi.org/10.1073/pnas.2319574121

Vancouver

Mouery BL, Baker EM, Mei L, Wolff SC, Mills CA, Fleifel D, et al. APC/C prevents a noncanonical order of cyclin/CDK activity to maintain CDK4/6 inhibitor–induced arrest. Proceedings of the National Academy of Sciences. 2024;121(30). doi:10.1073/pnas.2319574121

BibTeX
@article{Mouery2024,
  author = {Mouery, Brandon L and Baker, Eliyambuya M and Mei, Liu and Wolff, Samuel C and Mills, Christine A and Fleifel, Dalia and Mulugeta, Nebyou and Herring, Laura E and Cook, Jeanette Gowen},
  title = {APC/C prevents a noncanonical order of cyclin/CDK activity to maintain CDK4/6 inhibitor–induced arrest},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  volume = {121},
  number = {30},
  doi = {10.1073/pnas.2319574121}
}
Kostenlos starten →